Vivian Eisfeller

H. Lundbeck A/S is a global pharmaceutical company that specializes in the research, development, production, and marketing of drugs for the treatment of psychiatric and neurological disorders.

H. LUNDBECK A/S

h_lundbeck_a_s

Free Corporate Rating

• Condition: 1.5°C < SB2A ≤ 2°C
• Description: These companies, while not in the top tier of ‘leader’, still play a crucial role in advancing climate goals. Their activities are contributing substantially to climate objectives in their sectors and the climate transition.

● Condition: 3°C ≤ SB2A < 4°C or SB2A ≥ 2°C and increasing GHG intensity
● Description: Non-aligned companies face an urgent need for environmental improvement as their GHG intensity is increasing. With an SB2A Temperature indicating a substantial temperature misalignment (3°C ≤ SB2A < 4°C), these companies are recognized as having a high environmental impact. These companies are urged to prioritize and accelerate their sustainability initiatives to address their significant climate-related challenges.

• Condition: SB2A ≤ 1.5°C
• Description: Companies in this category demonstrate an exceptional commitment to the Paris Agreement. Their activities contribute significantly to maintaining global warming well below the 2-degree target, positioning them as leaders in enabling a sustainable future.

● Condition: SB2A ≥ 4°C
● Description: Laggard companies face a critical need for environmental improvement. With an SB2A Temperature indicating an extreme temperature misalignment (≥ 4°C), these companies are recognized as having the highest climate impact. These companies are urged to prioritize and accelerate their sustainability initiatives to address their significant climate-related challenges.

• Condition: 2°C ≤ SB2A < 3°C and decreasing GHG intensity and the company has established a target to reduce its GHG emissions
• Description: Companies in this category are actively positioning themselves for a sustainable transition. Their commitment is evident through a decrease in GHG intensity at company level, together with a certified targeted plan for further reduction and a decrease in temperature.

• Condition: 2°C ≤ SB2A < 3°C and decreasing GHG intensity without any target
• Description: Transitioning companies, despite the absence of a reduction target, are engaged in reducing their carbon footprint. The decrease in the GHG intensity at issuer level is the sign that these companies are making strides toward sustainability, even if a specific reduction target is yet to be formalized.

Rating peers in sector of {{sector}} (based on {{total}} companies)

Discover other companies in {{sector}} with {{score}} score

Climate Rating: Actively transitioning - H. Lundbeck A/S is a global pharmaceutical company that specializes in the research, development, production, and marketing of drugs for the treatment of psychiatric and neurological disorders.

Free Corporate Rating

H. LUNDBECK A/S

ISIN

LEI

Description

Rating peers in sector of Health Care (based on 275 companies)

19%

Leader

7%

Aligned

H. LUNDBECK A/S

4%

Actively
transitioning

29%

Transitioning

35%

Not
aligned

7%

Laggard

Discover other companies in Health Care with Actively transitioning score

Get in touch!

Free Corporate Rating

H. LUNDBECK A/S

ISIN

LEI

Description

Rating peers in sector of Health Care (based on 275 companies)

19%

Leader

7%

Aligned

H. LUNDBECK A/S

4%

Activelytransitioning

29%

Transitioning

35%

Notaligned

7%

Laggard

Discover other companies in Health Care with Actively transitioning score

Get in touch!

Actively
transitioning

Not
aligned